Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286235 | 0.96 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3417328 | 0.77 | — | — | |
| SCHEMBL9296811 | 0.73 | — | — | |
| SCHEMBL8515490 | 0.71 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12700286 | 0.71 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15095887 | 0.71 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1621071 | 0.70 | ALDH1A1 (0.32) | — | |
| SCHEMBL7227309 | 0.70 | — | — | |
| SCHEMBL22788167 | 0.68 | — | — | |
| SCHEMBL24752922 | 0.66 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652157-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | claimed |
| WO-2019012037-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2019-01-17 | — | — | WO | claimed |
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-07-05 | — | — | US | claimed |
| EP-3313518-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | Galderma Research & Development (FR) | 2018-05-02 | — | — | EP | claimed |
| EP-3212641-A1 | THIAZOLES AS MODULATORS OF RORyt | Janssen Pharmaceutica NV (BE) | 2017-09-06 | — | — | EP | claimed |
| WO-2017001433-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-01-05 | — | — | WO | claimed |
| WO-2016069976-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-06 | — | — | WO | claimed |
| US-9018212-B2 | Pyridazine carboxamides as CCR2 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-28 | — | — | US | claimed |
| EP-2576542-B1 | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | claimed |
| EP-2571870-B1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | claimed |
| US-8841313-B2 | CCR2 antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-23 | — | — | US | claimed |
| US-20130184299-A1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| EP-2576542-A1 | CCR2 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-04-10 | — | — | EP | claimed |
| EP-2571870-A1 | CCR2 ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2013-03-27 | — | — | EP | claimed |
| WO-2011147772-A1 | CCR2 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | WO | claimed |
| WO-2011144501-A1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | claimed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | claimed |
| US-6982263-B2 | Nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | claimed |
| WO-2005035500-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-21 | — | — | WO | claimed |
| US-4185014-A | Kentenimine intermediates for 6α-methoxy-α-carboxy penicillins | BEECHAM GROUP LIMITED (GB) | 1980-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | CALCRL, MRGPRX1, IL1RN | CHRM2 768/4885CHRM4 1318/4885CHRM5 1241/4885 |
| US-20130184299-A1 | CCR2 ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCL2 | CHRM2 153/4885CHRM4 382/4885CHRM5 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.